Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Peripheral Arterial Disease (PAD)- Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
"Peripheral Arterial Disease (PAD)- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral Arterial Disease (PAD) pipeline landscape is provided which includes the disease overview and Peripheral Arterial Disease (PAD) treatment guidelines.
This report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Peripheral Arterial Disease (PAD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The assessment part of the report embraces, in depth Peripheral Arterial Disease (PAD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral Arterial Disease (PAD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral Arterial Disease (PAD) R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral Arterial Disease (PAD).
Peripheral Arterial Disease (PAD) Emerging Drugs Chapters
This segment of the Peripheral Arterial Disease (PAD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Peripheral Arterial Disease (PAD) Emerging Drugs
Semaglutide: Novo Nordisk
Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Peripheral Artery Disease.
ACP 01: Hemostemix
ACP-01 is Hemostemix's lead product, designed as an autologous cell therapy for regenerating damaged tissues in patients with critical limb ischemia (CLI) and other vascular diseases. The treatment uses the patient's own stem cells, specifically angiogenic cell precursors (ACPs), which are harvested, processed, and then re-injected into areas of poor circulation.
These ACPs promote the growth of new blood vessels, aiming to restore blood flow and prevent amputations. ACP-01 has received orphan drug designation from the FDA and has shown promise in clinical trials, particularly for patients with no alternative treatment options. Currently, the drug is in the Phase II stage of its development for the treatment of Peripheral Arterial Disease.
Revacept: AdvanceCor
Revacept is the first Fc-fusion protein to be used as pharmaceutical in stroke and heart attack. With its GPVI component, Revacept binds to damaged blood vessel walls, covers them and thus forms a kind of vascular patch. This prevents the formation of thrombi in the arteries. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Peripheral Artery Disease.
Peripheral Arterial Disease (PAD): Therapeutic Assessment
Major Players in Peripheral Arterial Disease (PAD)
There are approx. 20+ key companies which are developing the therapies for Peripheral Arterial Disease (PAD). The companies which have their Peripheral Arterial Disease (PAD) drug candidates in the most advanced stage, i.e. Phase III include, Novo Nordisk.
Peripheral Arterial Disease (PAD): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peripheral Arterial Disease (PAD) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral Arterial Disease (PAD) drugs.
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Peripheral Arterial Disease (PAD) drugs?
- How many Peripheral Arterial Disease (PAD) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral Arterial Disease (PAD)?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peripheral Arterial Disease (PAD) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Peripheral Arterial Disease (PAD) and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- AdvanceCor
- Novo Nordisk
- Hemostemix
- Helixmith
- Aplagon
- Vasa Therapeutics
- IsomAb
Key Products
- Revacept
- Semaglutide
- ACP 01
- VM202
- APAC
- VS 367
- ISM-001
The report covers around 22+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Peripheral Arterial Disease (PAD) Report Insights
- Peripheral Arterial Disease (PAD) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Peripheral Arterial Disease (PAD) Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/1co6ua
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
